United States-based Sen-Jam Pharmaceuticals and United States-based development and manufacturing company KVK Tech, announced on Thursday that they are collaborating to develop a Covid-19 oral therapy.
Both firms are to operate in parallel while they complete the Phase II clinical trials in Nepal. KVK Tech is to provide formulation and chemistry, manufacturing and controls (CMC) for the oral therapy. KVK is also investing strategically in Sen-Jam to conclude the whole development activities required to provide the CMC package to the Food and Drug Administration (FDA) for submitting a new drug application (NDA).
Under the partnership, KVK will have exclusive manufacturing and supply rights for the product in the US, while Sen-Jam is to use the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT